About enVVeno Medical Corporation
https://www.envveno.comenVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency.
CEO
Robert A. Berman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-30 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:1.76M
Value:$635.19K
KINGDON CAPITAL MANAGEMENT, L.L.C.
Shares:1.36M
Value:$490.83K
VANGUARD GROUP INC
Shares:861.19K
Value:$310.98K
Summary
Showing Top 3 of 41
About enVVeno Medical Corporation
https://www.envveno.comenVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.76M ▼ | $-4.54M ▲ | 0% | $-0.23 ▲ | $-4.42M ▲ |
| Q2-2025 | $0 | $6.92M ▲ | $-6.69M ▼ | 0% | $-0.33 ▼ | $-6.56M ▼ |
| Q1-2025 | $0 | $4.83M ▼ | $-4.5M ▲ | 0% | $-0.22 ▲ | $-4.38M ▲ |
| Q4-2024 | $0 | $6.58M ▲ | $-6.23M ▼ | 0% | $-0.31 ▲ | $-6.11M ▼ |
| Q3-2024 | $0 | $6.04M | $-5.64M | 0% | $-0.35 | $-5.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $30.95M ▼ | $32.35M ▼ | $2.9M ▼ | $29.45M ▼ |
| Q2-2025 | $35.14M ▼ | $36.58M ▼ | $3.52M ▲ | $33.06M ▼ |
| Q1-2025 | $38.94M ▼ | $40.58M ▼ | $2.27M ▼ | $38.31M ▼ |
| Q4-2024 | $43.15M ▼ | $44.95M ▼ | $2.79M ▼ | $42.16M ▼ |
| Q3-2024 | $48.38M | $50.39M | $3.02M | $47.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.41M ▲ | $-4.39M ▼ | $3.65M ▲ | $241K ▲ | $-500K ▲ | $-4.39M ▼ |
| Q2-2025 | $-8.82M ▼ | $-3.71M ▲ | $2.82M ▼ | $0 | $-893K ▼ | $-3.72M ▲ |
| Q1-2025 | $-4.5M ▲ | $-4.02M ▲ | $5.2M ▲ | $0 | $1.18M ▲ | $-4.02M ▲ |
| Q4-2024 | $-6.23M ▼ | $-5.11M ▼ | $-11.06M ▼ | $0 ▼ | $-16.16M ▼ | $-5.11M ▼ |
| Q3-2024 | $-5.64M | $-4.28M | $6.22M | $13.59M | $15.54M | $-4.29M |
Revenue by Products
| Product | Q3-2018 | Q4-2018 | Q2-2019 | Q3-2019 |
|---|---|---|---|---|
 Royalty Income | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Contract Research Related Party | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Robert A. Berman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-30 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:1.76M
Value:$635.19K
KINGDON CAPITAL MANAGEMENT, L.L.C.
Shares:1.36M
Value:$490.83K
VANGUARD GROUP INC
Shares:861.19K
Value:$310.98K
Summary
Showing Top 3 of 41